胰升血糖素样肽1受体激动剂治疗2型糖尿病的Meta分析/系统评价再评价

GLP-1 receptor agonist for type 2 diabetes mellitus:an overview of systematic reviews/Meta-analysis

目的应用系统对已发表的胰升血糖素样肽1(GLP-1)受体激动剂治疗T2DM的系统评价/Meta分析进行再评价。方法计算机检索The Cochrane Library、Pub Med、EMBASE、CBM、万方数据库和中国知网数据库,搜集GLP-1受体激动剂治疗T2DM的系统评价/Meta分析,检索时限均为建库至2019年12月。由2名评价员独立筛选文献和提取资料后,采用AMSTAR量表和PRISMA声明,评价纳入研究的方法学质量及报告质量。结果最终纳入45篇研究。AMSTAR平均得分7.39分。PRISMA平均得分20.84分,报告质量存在的问题主要表现在方案与注册、文献检索及资助来源等方面。结论GLP-1受体激动剂治疗T2DM的系统评价/Meta分析方法学质量及报告质量偏低,有待提高。研究者应严格按照标准进行撰写及报告,提高方法学质量和报告质量,以提高临床证据的质量。

Objective To overview the published systematic reviews/Meta-analysis based on the efficacy and safety of GLP-1 receptor agonist in treatment of type 2 diabetes mellitus(T2DM).Methods A literature search was conducted with The Cochrane Library,Pub Med,EMBASE,CBM,Wanfang Data and CNKI from inception through December 2019.Two eligible studies screened literature and excluded data dependently.The methodological and reporting quality were evaluated by using the AMSTAR tool and the PRISMA checklist.Results Forty-five studies were included in this study.The average score of the AMSTAR tool was 7.39.The average score of PRISMA was 20.84.The main problems of reporting quality were in protocol,registration,search,additional analyses and funding.Conclusion The systematic evaluation/meta-analysis of GLP-1 receptor agonist in the treatment of T2DM needs to be improved due to the low quality of methodology and report.The future research should be written and reported in accordance with the standards strictly to improve the quality of methodology,report and clinical evidence.